Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SangStat Med. (SANG) - 10 of 10 analysts say Strong Buy -- Ignore unavailable to you. Want to Upgrade?

To: James Silverman who wrote (72)	2/8/1998 5:40:00 PM
From: John S. Sturges	Read Replies (2) \| Respond to of 184

My information is Thymoglobulin is 2-3yrs away from approval. It still needs a Phase III study to be considered for the application for which Zenapax has already been approved and is currently selling briskly for. Best regards, John

To: James Silverman who wrote (72)	2/8/1998 6:46:00 PM
From: pwrmstr	Read Replies (1) \| Respond to of 184

Thanks for correcting Sturges' mis-information. More specifically, Zenapax when used in combination with Cyclosporine reduces reject rates and adds no new side effects to those experiences when Cyclosporine is used by itself. This is highly different from Sturges' assertion that Zenapax is some sort of stand alone miracle side-effect free replacement for Cyclosporine. In fact PDLI discontinued Phase II/III clinical trials on Zenapax in the last year or two when they found it was ineffective as a stand-alone therapy for transplant rejection. This article can be found by searching for Zenapax under Infoseek. If there are new studies to the contrary, I would love for Sturges to post more information on them. Just to be safe, I am going to call my contacts at Roche and the doctors I know in ASTP tomorrow to find out if there is any validity to Sturges' claims. For now, I find too many inaccuracies in his posting to lend much credence to his assertions. IMO now is a great time to add to positions in Sangstat given the pending FDA approval. I just bought at 28 and will add further below 25 if we get there. Obviously, all bets are off if in the unlikely event Sturges' assertions are true. John Rowe